simurosertib   Click here for help

GtoPdb Ligand ID: 10317

Synonyms: example 108 [US9655900B2] | TAK-931 | TAK931
PDB Ligand
Compound class: Synthetic organic
Comment: Simurosertib (TAK-931) is an oral Cdc7 (cell division cycle 7-related protein kinase) inhibitor that is being developed by Millennium Pharmaceuticals/Takeda for potential antineoplastic activity in CDC7-overexpressing tumour cells [3]. Cdc7 is a serine/threonine kinase and cell division cycle protein. Simurosertib sensitizes tumour cells to DNA-damaging chemotherapies by functioning to disrupt the cells' ability to recover from DNA damage [2].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 2
Topological polar surface area 105.91
Molecular weight 341.13
XLogP 1.96
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Cc1[nH]ncc1c1sc2c(c1)nc([nH]c2=O)C1CC2CCN1CC2
Isomeric SMILES Cc1[nH]ncc1c1sc2c(c1)nc([nH]c2=O)[C@@H]1CC2CCN1CC2
InChI InChI=1S/C17H19N5OS/c1-9-11(8-18-21-9)14-7-12-15(24-14)17(23)20-16(19-12)13-6-10-2-4-22(13)5-3-10/h7-8,10,13H,2-6H2,1H3,(H,18,21)(H,19,20,23)/t13-/m0/s1
InChI Key XGVXKJKTISMIOW-ZDUSSCGKSA-N
References
1. Homma M, Miyazaki T, Oguru Y, Kurasawa O. (2017)
Heterocyclic compound.
Patent number: US9655900B2. Assignee: Takeda Pharmaceutical Co Ltd. Priority date: 17/02/2010. Publication date: 23/05/2017.
2. Iwai K, Nambu T, Kashima Y, Yu J, Eng K, Miyamoto K, Kakoi K, Gotou M, Takeuchi T, Kogame A et al.. (2021)
A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery.
Sci Adv, 7 (21). DOI: 10.1126/sciadv.abf0197 [PMID:34020950]
3. Kurasawa O, Miyazaki T, Homma M, Oguro Y, Imada T, Uchiyama N, Iwai K, Yamamoto Y, Ohori M, Hara H et al.. (2020)
Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-d]pyrimidinone-Based Cdc7 Inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Antitumor Agent.
J Med Chem, 63 (3): 1084-1104. [PMID:31895562]